HK1189591A1 - Hydrochloride salt of 5-r3-f3-tivdroxyphenoxy)azetidi-1-v-5-methyl-2 2- diphenylhexanamide 5-[3-(3-)-1-]-5--22- - Google Patents

Hydrochloride salt of 5-r3-f3-tivdroxyphenoxy)azetidi-1-v-5-methyl-2 2- diphenylhexanamide 5-[3-(3-)-1-]-5--22-

Info

Publication number
HK1189591A1
HK1189591A1 HK14102704.7A HK14102704A HK1189591A1 HK 1189591 A1 HK1189591 A1 HK 1189591A1 HK 14102704 A HK14102704 A HK 14102704A HK 1189591 A1 HK1189591 A1 HK 1189591A1
Authority
HK
Hong Kong
Prior art keywords
tivdroxyphenoxy
diphenylhexanamide
azetidi
methyl
hydrochloride salt
Prior art date
Application number
HK14102704.7A
Other languages
English (en)
Chinese (zh)
Inventor
．格羅索普
．詹姆斯
Original Assignee
輝瑞有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39591485&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1189591(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 輝瑞有限公司 filed Critical 輝瑞有限公司
Publication of HK1189591A1 publication Critical patent/HK1189591A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK14102704.7A 2007-03-16 2014-03-18 Hydrochloride salt of 5-r3-f3-tivdroxyphenoxy)azetidi-1-v-5-methyl-2 2- diphenylhexanamide 5-[3-(3-)-1-]-5--22- HK1189591A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89516307P 2007-03-16 2007-03-16

Publications (1)

Publication Number Publication Date
HK1189591A1 true HK1189591A1 (en) 2014-06-13

Family

ID=39591485

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14102704.7A HK1189591A1 (en) 2007-03-16 2014-03-18 Hydrochloride salt of 5-r3-f3-tivdroxyphenoxy)azetidi-1-v-5-methyl-2 2- diphenylhexanamide 5-[3-(3-)-1-]-5--22-

Country Status (24)

Country Link
US (1) US8263583B2 (xx)
EP (1) EP2125714B1 (xx)
JP (1) JP4277051B2 (xx)
KR (1) KR101120227B1 (xx)
CN (2) CN101641327A (xx)
AR (1) AR065714A1 (xx)
AT (1) ATE512132T1 (xx)
AU (1) AU2008247095B2 (xx)
BR (1) BRPI0808413A2 (xx)
CA (1) CA2678683C (xx)
CY (1) CY1111701T1 (xx)
DK (1) DK2125714T3 (xx)
ES (1) ES2364727T3 (xx)
HK (1) HK1189591A1 (xx)
IL (1) IL200403A (xx)
MX (1) MX2009009952A (xx)
NZ (1) NZ579056A (xx)
PL (1) PL2125714T3 (xx)
PT (1) PT2125714E (xx)
RU (1) RU2422439C2 (xx)
SI (1) SI2125714T1 (xx)
TW (1) TWI348907B (xx)
WO (1) WO2008135819A1 (xx)
ZA (1) ZA200906462B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599774A (en) 2009-11-23 2014-11-28 Palatin Technologies Inc Melanocortin-1 receptor-specific cyclic peptides
EA201290295A1 (ru) 2009-11-23 2013-01-30 Палатин Текнолоджиз, Инк. Специфичные к рецептору меланокортина-1 линейные пептиды
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP3596046A1 (en) * 2017-03-15 2020-01-22 Mylan Laboratories Ltd. Novel polymorphs of (5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide hydrochloride
CA3128468A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2020261160A1 (en) * 2019-06-25 2020-12-30 Mylan Laboratories Limited Methods and intermediates for preparing hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
CN116033893A (zh) * 2020-06-26 2023-04-28 迈兰制药英国有限公司 包含5-[3-(3-羟基苯氧基)氮杂环丁烷-1-基]-5-甲基-2,2-二苯基己酰胺的制剂
CN113577059B (zh) * 2021-08-02 2022-05-20 山东大学齐鲁医院(青岛) 一种用于小儿哮喘的活性药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69720518T2 (de) * 1996-12-02 2004-02-26 Kyorin Pharmaceutical Co., Ltd. Neue derivate von n-substituierten pyrrolidin derivaten und deren herstellungsverfahren
JPH11100366A (ja) 1997-09-29 1999-04-13 Kyorin Pharmaceut Co Ltd 新規ｎ−置換環状アミン誘導体及びその製造法
EP1928821B1 (en) * 2005-09-21 2009-01-07 Pfizer Limited Carboxamide derivatives as muscarinic receptor antagonists
WO2008035157A1 (en) * 2006-09-22 2008-03-27 Pfizer Limited Azetidine derivatives as muscarinic receptor antagonists

Also Published As

Publication number Publication date
WO2008135819A8 (en) 2009-08-27
TWI348907B (en) 2011-09-21
IL200403A0 (en) 2010-04-29
PL2125714T3 (pl) 2011-10-31
RU2009134512A (ru) 2011-03-20
AR065714A1 (es) 2009-06-24
CN103351367B (zh) 2015-06-10
US20100113409A1 (en) 2010-05-06
WO2008135819A1 (en) 2008-11-13
ZA200906462B (en) 2010-06-30
EP2125714A1 (en) 2009-12-02
RU2422439C2 (ru) 2011-06-27
US8263583B2 (en) 2012-09-11
SI2125714T1 (sl) 2011-10-28
IL200403A (en) 2014-08-31
EP2125714B1 (en) 2011-06-08
ES2364727T3 (es) 2011-09-13
CA2678683A1 (en) 2008-11-13
CY1111701T1 (el) 2015-10-07
CN101641327A (zh) 2010-02-03
NZ579056A (en) 2011-07-29
DK2125714T3 (da) 2011-07-25
AU2008247095B2 (en) 2012-12-13
KR101120227B1 (ko) 2012-03-20
AU2008247095A1 (en) 2008-11-13
MX2009009952A (es) 2009-10-08
JP2009001543A (ja) 2009-01-08
CN103351367A (zh) 2013-10-16
KR20090110944A (ko) 2009-10-23
PT2125714E (pt) 2011-07-14
CA2678683C (en) 2012-05-15
ATE512132T1 (de) 2011-06-15
TW200904408A (en) 2009-02-01
BRPI0808413A2 (pt) 2014-07-15
JP4277051B2 (ja) 2009-06-10

Similar Documents

Publication Publication Date Title
HK1189591A1 (en) Hydrochloride salt of 5-r3-f3-tivdroxyphenoxy)azetidi-1-v-5-methyl-2 2- diphenylhexanamide 5-[3-(3-)-1-]-5--22-
IL197420A0 (en) Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-
IL212186A0 (en) Fungicidal heterocyclic compounds
ZA201006511B (en) Heterocyclic compound
EP2269990A4 (en) HETEROCYCLIC COMPOUND
EP2192838A4 (en) HETEROCYCLIC NEKROPTOSIS HEMMER
ZA201103887B (en) Isoxazole derivatives for use as fungicides
ZA201006505B (en) Novel heterocyclic compounds and uses thereof
HK1148283A1 (en) Heterocyclic derivatives
EP2202223A4 (en) HETEROCYCLIC COMPOUND
IL200329A0 (en) 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
GB0700194D0 (en) Humanisation of animals
EP2196459A4 (en) 5-GROUND HETEROCYCLIC COMPOUND
PL2254887T3 (pl) Pochodne oksazolidynonu
IL195158A0 (en) Novel heterocyclic compounds
EP2210876A4 (en) HETEROCYCLIC CONNECTION
EP2295406A4 (en) HETEROCYCLIC CONNECTION
HRP20150932T1 (xx) Heterocikliäśki spojevi
ZA201002580B (en) Heterocyclic derivatives
GB0612508D0 (en) Crystalline duloxetine hydrochloride
GB0700830D0 (en) Crystalline duloxetine hydrochloride
GB0612506D0 (en) Crystalline duloxetine hydrochloride
GB0921210D0 (en) Novel heterocyclic derivatives
EP2189445A4 (en) FIVE-GLASS HETEROCYCLIC CONNECTION
GB0619308D0 (en) Heterocyclic compounds